Omnipaque™ (Iohexol)

Adverse events should be reported to GE HealthCare at:

gpv.drugsafety@gehealthcare.com

REFERENCES

1. Middle East Omnipaque Summary of Product Characteristics, January 2023
2. Data on File,GE HealthCare,Omnipaque Demand_2022
3. Gomi T et al. Eur Radiol 2010; 10(7):1631-5
4. Parakh A et al. Radiology 2019; 291(3): 620-29
5. McNamara M et al. Am J Roentgenol 2010; 195: 1137–41.
6. Smevik B, Westvik J. Acta Radiol 1990; 31: 601–4.
7. Marshall G. Radiography 2008; 14:128-34
8. Gricar J et al. Radiology Management 2007: Sept/Oct 34-42
9. Dhaliwal H et al. Int J Life Cycle Assess (2014) 19:1965-73
10. Sudgen D. Presented at Middle East North CT Radiographer Work. Leeds, March 2017
11. Lamb JT. Invest Radiol 1985; 20(Suppl.) S37–S43.
12. Rubin CME et al. Brit J Radiol 1987; 60: 133–5.
13. Harding JR et al. Brit J Radiol 1995; 68: 712–5.
14. Katayama H et al. Invest Radiol 2001; 36: 22–32.
15. Faykus MH et al. Invest Radiol 1994; 29 (Suppl.1): S98–S101.
16. Bischoff W. Fortschr Röntgenstr 1989; 128: 108–10.
17. Drouillard J et al. Acta Radiol 1996; 37 (Suppl.400): 56–61.
18. Legmann P et al. Eur Radiol 2001; 11: 2220–7.
19. Kaufman AJ et al. Urol Radiol 1990; 12: 56–60.
20. Cutcliff WB et al. Invest Radiol 1989; 24 (Suppl.1): S56–9.
21. Bertrand P et al. Acad Radiol 1995; 2: 683–6.
22. Krouwels MM et al. Eur J Radiol 1996; 22: 133–5.